Therapeutic options in androgen-independent prostate cancer: Building on docetaxel

BJU International, Supplement

Volumn 96, Issue 2, 2005, Pages 41-46

  Petrylak, Daniel ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Androgen independent prostate cancer; Calcitriol; Docetaxel; Estramustine; Paclitaxel; PSA; Thalidomide

Indexed keywords

ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; BORTEZOMIB; CALCITRIOL; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; HYDROCORTISONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUJ591; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANGIOGENESIS; APOPTOSIS; BLOOD LEVEL; BONE PAIN; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOXICITY; DUODENUM ULCER; GASTROINTESTINAL SYMPTOM; HORMONE RESISTANCE; HUMAN; LUNG EMBOLISM; MALE; METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; STOMACH ULCER; SYMPTOM; THROMBOSIS;

ANDROGENS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ESTRAMUSTINE; HUMANS; MALE; MITOXANTRONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 29944434214     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05946.x     Document Type: Conference Paper

References (62)

1. Culine S, Droz J-P. Chemotherapy in advanced androgen-independent prostate cancer 1990-99: a decade of progress? Ann Oncol 2000; 11: 1523-30
2. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7
3. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001; 53: 73-91
4. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (Suppl. 3): 1098-109
5. Roth BJ. Combination chemotherapy in advanced prostate cancer: a silk purse? J Clin Oncol 1994; 12: 2001-2
6. Smith MR. Association between androgen deprivation therapy and fracture risk: a population-based cohort study in med with non-metastatic prostate cancer. Proc Am Soc Clin Oncol 2004; 23: 394, A4507
7. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439-43
8. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
9. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002; 20 (Suppl. 1): 31-5
10. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54 (Suppl. 6A): 30-5
11. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984; 142: 773-6
12. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607-15
13. D'Amico AV, Halabi S, Vogelzang NJ, Small FJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: results of a pooled analysis of CALBG HRPC trials. Proc Am Soc Clin Oncol 2004; 23: A4506
14. Collette L, Burzykowski T, Carroll K, Newling D, Morris T, Schroder F. Is prostate-specific antigen a surrogate for survival in advanced prostate cancer? Proc Am Soc Clin Oncol 2004; 23: 394, A4551
15. Crawford ED, Pauler DK, Tangen DM et al. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. Proc Am Soc Clin Oncol 2004; 23: 394, A4501
16. La Rocca RV, Danesi R, Cooper MR et al. Effect of suramin on human prostate cancer cells in vitro. J Urol 1991; 145: 393-8
17. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-56
18. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-13
19. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-5
20. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26 (Suppl. 17): 14-8
21. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457-60
22. Trivedi C, Redman B, Flaherty LE et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000; 89: 431-6
23. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17: 958-67
24. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000; 27 (Suppl. 3): 24-9
25. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALBG 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-16
26. Weitzman AL, Shelton G, Zuech N et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer J Urol 2000; 163: 834-7
27. Petrylak DP, Tangen CM, Hussein MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
28. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
29. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997; 15: 13-9
30. Hudes GR, Greenberg R, Krigel RL et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992; 10: 1754-61
31. Labrie F, Dupont A, Giguere M et al. Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur J Cancer Clin Oncol 1988; 25: 1255-60
32. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827-41
33. Hudes Q, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17: 3160-6
34. Hershberger PA, Yu W-D, Modzelewski RA, Rueger RM, Johnson CS, Trump DL Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001; 7: 1043-51
35. Blutt SE, McDonnell TJ, Polek TC, Weigel NL Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000; 141: 10-7
36. 3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002; 143: 2508-14
37. Beer TM, Eilers KM, Garzotto M, Egaorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-8
38. Novacea. http://www.novacea.com/431.asp. Accessed September 2004
39. Figg WD, Dahut W, Duray P et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1888-93
40. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532-9
41. Retter AS, Ando YK, Gulley JL et al. Follow-up analysis of a randomized phase Il study of docetaxel (D) and thalidomide (T) in androgen-independent prostate cancer (AIPC): updated survival data and stratification by CYP2C19 mutations. Prostate Cancer Symposium 2005. Proc Am Soc Clin Oncol 2005; 24: A265
42. George DJ, Haiabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-6
43. Picus J, Halabi S, Rini B et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22: 393, A1578
44. National Cancer Institute. Docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy. Available at: www.clinicaltrials.gov/ct/show/nct00110214?order= 1. Accessed September 2005
45. Fisher M. The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer. Clin Prostate Cancer 2002; 1: 79-80
46. Yount S, Cella D, Mulani D et al. Impact of atrasentan on prostate-specific outcomes with hormone refractory prostate cancer patients. Proc Am Soc Clin Oncol 2004; 23: 401, A4582
47. Carducci M, Nelson JB, Saad F et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. Proc Am Soc Clin Oncol 2004; 23: 383, A4508
48. Yuyama H, Sanagi M, Koakutsu A et al. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist. Eur J Pharmacol 2003; 478: 61-71
49. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30: 667-76
50. Nanus DM, Milowsky MI, Kostakoglu L et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170:S84-9
51. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23: 4591-601
52. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-κB in prostate cancer lymph node metastases. Prostate 2004; 58: 308-13
53. Chen DC, Sawyers CL NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002; 22: 2862-70
54. Flynn V Jr, Ramanitharan A, Moparty K et al. Adenovirus-mediated inhibition of NF-κB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol 2003; 23: 317-23
55. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002; 6: 493-500
56. Papandreou CN, Daliani DD, Nix D et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21
57. Dreicer R, Roth B, Petrylak D et al. Bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer: A phase 1/2 study. Prostate Cancer Symposium 2005. Proc Am Soc Clin Oncol 2005; 24: A250
58. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
59. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-8
60. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 2000; 86: 675-80
61. Rosenbaum E, Kibel A, Roth BJ et al. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): preliminary data of a multicenter pilot trial. Proc Am Soc Clin Oncol 2004; 23: A4649
62. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20: 4567-73